The Patent Finder

CuRNA, Inc.

50 patents currently held · Updated Nov 22, 2026
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Previously recorded as Opko Curna, LLC (to 2012)

26
Ending by 2030
Aug 2029
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 4 fees due Dec 2 to 30, 2026 · next Dec 2
  • 7 fees due Jan 2 to 28, 2027 · next Jan 2
  • 1 fee due Feb 6, 2027
    The maintenance fee for Treatment of Collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene (US 10,370,657) comes due Feb 6, 2027. Unpaid by Aug 6, 2027, it lapses early.
  • 1 fee due Mar 15, 2027
    The maintenance fee for Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene (US 9,133,456) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
  • 4 fees due Apr 8 to 22, 2027 · next Apr 8
  • 2 fees due May 3 to 5, 2027 · next May 3
  • 3 fees due Jun 1 to 30, 2027 · next Jun 1
  • 1 fee due Aug 23, 2027
    The maintenance fee for Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene (US 9,267,136) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
  • 2 fees due Sep 10 to 30, 2027 · next Sep 10

Which patents, and when each one lapses · Pro

Recent changes

  • 2 terms have ended since Aug 24, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,133,456Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
In force
 · USPTO record
In forceUSPTO record
US 8,153,606Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
In force
 · USPTO record
In forceUSPTO record
US 8,921,329Treatment of Erythropoietin (EPO) Related Diseases by Inhibition of Natural Antisense Transcript to Epo
In force
 · High confidence
In forceHigh confidence
US 10,358,645Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO
In force
 · USPTO record
In forceUSPTO record
US 10,358,646Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
In force
 · USPTO record
In forceUSPTO record
US 11,697,814Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
In force
 · USPTO record
In forceUSPTO record
US 10,519,448Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF
In force
 · USPTO record
In forceUSPTO record
US 10,465,192Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1
In force
 · USPTO record
In forceUSPTO record
US 9,163,285Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP
In force
 · USPTO record
In forceUSPTO record
US 10,604,755Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
In force
 · USPTO record
In forceUSPTO record
10 of 50 patents shown.
Pro members see all 50.
Pro members: see all 50 patents
Also on record, not counted in the 50: 2 patents in force now held by others · 61 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

2 abandoned · 12 no status recorded

Showing 1 to 10 of 14, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
17/547,791Dec 10, 2021No status recorded
16/886,902May 29, 2020No status recorded
16/163,096Oct 17, 2018No status recorded
15/925,266Mar 19, 2018No status recorded
15/689,754Aug 29, 2017No status recorded
14/957,064Dec 2, 2015No status recorded
14/849,979Sep 10, 2015No status recorded
14/703,046May 4, 2015No status recorded
14/629,768Feb 24, 2015No status recorded
14/384,659Treatment of Brain Derived Neurotrophic Factor (BDNF) Related Diseases by Inhibition of Natural Antisense Transcript to BDNFMar 12, 2013Abandoned
10 of 14 applications shown.
Pro members see all 14 published applications.
Pro members: see all 14 applications
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited